Table 3. Regional clone and copy number alterations and patient/tumor characteristics.

Sex	Clone with highest signal	Region altered	Start (Mb)	End	P-value adja	Male (%)/female (%)	OR (MV)b,c	95% CIb	P-valueb
1q+	RP11-188A4 (1q43-44)	1q43-44	239 316.500	2.39E+08	0.002	17/9	2.56	(1.43–4.55)	0.04
6p−	RP11-52C20 (6p22)	6p22, 24-25	23 943.950	24 112 567	0.01	22/11	2.22	(1.18–4.17)	0.003
9q−	RP11-19014 (9q13)	9q13, 21.1-22, 33	70 455.470	70 634 947	0.003	38/21	2.13	(1.30–3.57)	0.001
12p+	RP11-174L5(12p12.3)	12p12.3	14 735.670	14 736 047	0.001	38/19	2.44	(1.45–4.00)	0.001
12q+	RP11-29G23 (12q12.4)	12q12.4, 24-tel	43 908.780	43 909 199	0.02	25/14	1.92	(1.11–3.33)	0.004
Family history						No (%)/yes (%)
4q−	RP11-7G22 (4q21.3-22)	4q21-23	84 523.610	84 723 458	0.002	24/11	2.70	(1.45–5.26)	0.002
20q+	RP11-15M15 (20q13.2)	20q13.2	51 109.650	51 266 870	0.003	26/13	2.38	(1.41–4.55)	0.002
Ever smoker						Never (%)/ever (%)
16p+	RP11-150K5 (16p11.2)	16p11.2-13.2	29 825.190	29 825 404	0.003	11/22	2.72	(1.42–5.21)	0.003
3q−	CTD-2014B13 (3q13.2)	3q12-14	100 971.500	1.01E+08	0.03	24/40	1.73	(1.06–2.83)	0.04
Von Hippel–Lindau gene alteration						Wild-type (%)/altered (%)
3p−	RP11-180G14 (3p14.3)	3p14.3	59 538.560	59 538 883	0.02	71/92	4.88	(2.23–10.68)	<0.00001
	RP11-245E5 (3p24)	3p21-25, tel	22 747.910	22 936 416	1.97E-07	63/95	13.48	(6.01–30.20)	<0.00001
20q+	LLNL-255K9 (20q13.2)	20q11-13.2	55 338.240	55 352 455	0.03	33/20	2.08	(1.04–4.17)	0.03

Abbreviations: CI, confidence interval; MV, multivariate model; OR, Odds Ratio.

^aP-value adjusted for multiple comparisons.

^bOR, 95% CI and P-values from MV adjusted for age, sex, country stage, grade, smoking status and family history of cancer.

^cORs presented for most prevalent comparison group (underlined).